Success Metrics

Clinical Success Rate
88.2%

Based on 15 completed trials

Completion Rate
88%(15/17)
Active Trials
0(0%)
Results Posted
107%(16 trials)
Terminated
2(11%)

Phase Distribution

Ph phase_2
6
32%
Ph phase_1
11
58%
Ph phase_3
1
5%

Phase Distribution

11

Early Stage

6

Mid Stage

1

Late Stage

Phase Distribution18 total trials
Phase 1Safety & dosage
11(61.1%)
Phase 2Efficacy & side effects
6(33.3%)
Phase 3Large-scale testing
1(5.6%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

83.3%

15 of 18 finished

Non-Completion Rate

16.7%

3 ended early

Currently Active

0

trials recruiting

Total Trials

19

all time

Status Distribution
Completed(15)
Terminated(3)
Other(1)

Detailed Status

Completed15
Terminated2
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
19
Active
0
Success Rate
88.2%
Most Advanced
Phase 3

Trials by Phase

Phase 111 (61.1%)
Phase 26 (33.3%)
Phase 31 (5.6%)

Trials by Status

unknown15%
terminated211%
withdrawn15%
completed1579%

Recent Activity

0 active trials
Showing 5 of 19
completedphase_3

A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma

NCT02451943
unknown

Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma

NCT03994627
completedphase_1

A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma

NCT03126591
completedphase_1

A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer

NCT03086369
completedphase_1

A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma

NCT02659020
View all 19 trials

Clinical Trials (19)

Showing 19 of 19 trials
NCT02451943Phase 3

A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma

Completed
NCT03994627

Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma

Unknown
NCT03126591Phase 1

A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma

Completed
NCT03086369Phase 1

A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer

Completed
NCT02659020Phase 1

A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma

Completed
NCT02377752Phase 1

A Study of Olaratumab in Japanese Participants With Advanced Cancer

Completed
NCT03283696Phase 1

A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma

Completed
NCT03698227Phase 2

OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients

Terminated
NCT02677116Phase 1

A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer

Completed
NCT02326025Phase 1

A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma

Completed
NCT00913835Phase 2

A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer

Completed
NCT01204710Phase 2

A Study of Olaratumab (IMC-3G3) in Prostate Cancer

Completed
NCT02783599Phase 1

A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma

Completed
NCT03437070Phase 1

Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma

Withdrawn
NCT00918203Phase 2

A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Completed
NCT00895180Phase 2

Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme

Completed
NCT01199822Phase 1

Study of the Safety and Pharmacokinetics of Olaratumab (IMC-3G3) in Japanese Participants With Solid Tumors

Completed
NCT01185964Phase 1

A Study of Olaratumab in Soft Tissue Sarcoma

Completed
NCT01316263Phase 2

A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors

Terminated

All 19 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
19